再组合人体内静止素作为潜在的抗血管原体:治疗前景和当前状态
J Anakha1, Prakashkumar Dobariya1, Shyam Sunder Sharma2
1Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali, Punjab, 160062, India.
Medical oncology (Northwood, London, England)
|December 20, 2023
概括
血管新生抑制剂提供癌症治疗的潜力,但毒性和成本驱动研究更安全的替代品,如内静止素. 复合人体内静止素 (rh-Es) 在各种癌症的临床试验中显示出有前途.
科学领域:
- 在瘤学瘤学.
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管新生,新血管的形成,对于生理过程和癌症生长至关重要.
- 抑制血管生成是癌症治疗的关键策略,现有的药物面临毒性和成本挑战.
- 内静素是一种内源性抗血管原因子,已经显示出潜力,但需要进一步开发.
研究的目的:
- 审查目前用于癌症治疗的抗血管新生药物.
- 为了总结瘤血管生成在内静止素的背景下.
- 讨论复合人体内静止素 (rh-Es) 的临床状态和改善策略.
主要方法:
- 对抗血管生成疗法的文献综述.
- 对瘤血管生成机制的分析.
- 对内静止素和rh-Es的临床试验数据的评估.
主要成果:
- 现有的抗血管性药物在毒性和可负担性方面存在局限性.
- 复合人体内静止素 (rh-Es) 已在非小细胞肺癌和其他恶性瘤中显示出有效性.
- 目前正在进行的试验和已完成的研究表明,基于内静止素的疗法有希望的结果.
结论:
- 尽管存在局限性,但内静止素仍然是一个有前途的抗血管原体.
- 改善rh-Es药理动力学特性的策略对于其更广泛的应用至关重要.
- rh-Es具有作为安全有效的癌症治疗选择的潜力.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


